In addition, in VPA-treated AD transgenic mouse model, Tau hyperphosphorylation at Ser396 and Ser262 was significantly reduced in the study conducted by Long et al. (2015) (Long et al. 2015). The gene discussed is MAPT; the disease is Alzheimer disease.